Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- Publicado em
- 31 jan 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma
Gael S Roth, Jérôme Cros, Cindy Neuzillet, Emilie Barbier, Meriem Guarssifi, Amel Bennacer, Michel Ducreux, Marie Muller, Julien Edeline, Sylvain Manfredi et al.
Descritores MeSH
- Ampulla of Vater
- Capecitabine
- Common Bile Duct Neoplasms
- Deoxycytidine
- Adenocarcinoma
- Antineoplastic Combined Chemotherapy Protocols
- Aged
- Adult
- Oxaliplatin
- Leucovorin
Veja também
Estudos relacionados
- Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
- A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
- Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
- SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)